Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. saw a rise in stock price today, contrasting with a decline in the broader market. However, the company has struggled over the past year, with significant declines in stock performance and net profit, highlighting ongoing challenges in the pharmaceuticals sector.

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. saw a notable increase in its stock price today, reaching an intraday high. The company has outperformed the China Shanghai Composite in recent days, though it faces longer-term challenges with declines over the past month and year-to-date. Its market capitalization is CNY 12,990 million.

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. saw a significant increase today, contrasting with the broader market's modest gains. While the company has shown a positive trend recently, its long-term performance reveals substantial declines over the past year and three years, alongside mixed financial metrics and a modest dividend yield.

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. faced a decline in stock performance, with significant drops over various time frames. The company has struggled with negative net profit growth and low interest coverage, raising concerns about its financial stability despite a high dividend yield. It continues to underperform against the broader market.